You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

janus kinase

Showing 51 - 75 of 2,152
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Haemophagocytic Lymphohistiocytosis Trial (Ruxolitinib)

Not yet recruiting
  • Haemophagocytic Lymphohistiocytosis
  • (no location specified)
Feb 28, 2023

Rheumatoid Arthritis Trial in Dhaka (Baricitinib 2 MG, Methotrexate 25mg)

Recruiting
  • Rheumatoid Arthritis
  • Baricitinib 2 MG
  • Methotrexate 25mg
  • Dhaka, Bangladesh
    Dr. Md. Abu Shahin
Apr 12, 2023

Application of N-of-1 Rheumatoid Arthritis

Not yet recruiting
  • Arthritis, Rheumatoid
  • Boston, Massachusetts
    Tufts Medical Center
Aug 24, 2023

Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts

Not yet recruiting
  • Warts
  • Detection of expression of SOCS3 gene
  • +2 more
  • (no location specified)
Mar 12, 2023

Human Immunodeficiency Virus Trial in Atlanta (Baricitinib 2 MG Oral Tablet, Placebo)

Not yet recruiting
  • Human Immunodeficiency Virus
  • Baricitinib 2 MG Oral Tablet
  • Placebo
  • Atlanta, Georgia
  • +1 more
Aug 11, 2022

Alopecia Areata Trial in Assiut (Betamethasone Valerate 0.1% Cream, Pentoxifylline, Metformin)

Not yet recruiting
  • Alopecia Areata
  • Betamethasone Valerate 0.1% Cream
  • +2 more
  • Assiut, Egypt
    Assiut university
Oct 15, 2023

Dermatomyositis, Adult Type Trial in Xi'an (JAK Inhibitor)

Recruiting
  • Dermatomyositis, Adult Type
  • JAK Inhibitor
  • Xi'an, Shaanxi, China
    Department of Rheumatology, the First Affiliated Hospital of Xi'
Jul 15, 2021

T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated Trial run by the NCI (Ruxolitinib,

Completed
  • T Cell Leukemia, Adult
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jan 26, 2022

Cytokine Release Syndrome Trial in United States (Itacitinib, Immune effector cell therapy, Placebo)

Recruiting
  • Cytokine Release Syndrome
  • Miami, Florida
  • +9 more
Oct 25, 2022

Graft Vs Host Disease, GVHD Trial in Tampa, Minneapolis (Pacritinib, Sirolimus, Tacrolimus)

Active, not recruiting
  • Graft Vs Host Disease
  • GVHD
  • Tampa, Florida
  • +1 more
Jul 27, 2022

Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

Recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 18, 2022

Dermatitis, Atopic, Pruritus Trial in United States (ASN008, ASN008 Matching Vehicle)

Recruiting
  • Dermatitis, Atopic
  • Pruritus
  • Scottsdale, Arizona
  • +17 more
May 24, 2023

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Columbus, Ohio
  • +2 more
Aug 10, 2022

Healthy Trial in New Haven (Ritlecitinib 50 mg, Ritlecitinib 200 mg)

Completed
  • Healthy
  • Ritlecitinib 50 mg
  • Ritlecitinib 200 mg
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Feb 4, 2022

Dermatomyositis Trial in Baltimore (Tofacitinib)

Completed
  • Dermatomyositis
  • Baltimore, Maryland
    Johns Hopkins University
Nov 5, 2020

Rheumatoid Arthritis Trial in Abu Dhabi (Anti-TNF, JAK inhibitor)

Not yet recruiting
  • Rheumatoid Arthritis
  • Abu Dhabi, United Arab Emirates
    Abu Dhabi Stem Cells Center
May 17, 2022

Atopic Dermatitis Trial in China (SHR0302 Ointment, Vehicle)

Recruiting
  • Atopic Dermatitis
  • Beijing, Beijing, China
  • +20 more
Jun 3, 2022

Myeloproliferative Tumors Trial in Canada, Spain, United States (VAC85135, Ipilimumab)

Recruiting
  • Myeloproliferative Neoplasms
  • Birmingham, Alabama
  • +16 more
Jan 27, 2023

Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Itacitinib (INCB039110)
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Jul 14, 2022

IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)

Recruiting
  • IDH Mutation
  • +4 more
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

Recruiting
  • BCR-JAK2 Fusion Protein Expression
  • +11 more
  • Palo Alto, California
  • +3 more
Oct 5, 2022

Myelofibrosis Trial in United States (Selinexor, Ruxolitinib)

Recruiting
  • Myelofibrosis
  • Duarte, California
  • +4 more
Jan 30, 2023

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Worldwide (Pelabresib, Ruxolitinib, Placebo)

Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +148 more
Oct 10, 2022

Myelofibrosis Trial in Changchun (TQ05105 Tablets)

Completed
  • Myelofibrosis
  • TQ05105 Tablets
  • Changchun, Jilin, China
    Affiliated Hospital of Changchun University of Traditional Chine
Aug 1, 2023

Myelofibrosis Trial in Worldwide (Selinexor, Physician's Choice Treatment)

Recruiting
  • Myelofibrosis
  • Los Angeles, California
  • +41 more
Jan 30, 2023